<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925847</url>
  </required_header>
  <id_info>
    <org_study_id>P080401</org_study_id>
    <nct_id>NCT00925847</nct_id>
  </id_info>
  <brief_title>Effect of Lithium Carbonate in Patients With Amyotrophic Lateral Sclerosis</brief_title>
  <acronym>LISLA</acronym>
  <official_title>Open Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether lithium is safe and effective in the&#xD;
      treatment of ALS&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Daily doses of lithium, have been found to delay progression of amyotrophic lateral sclerosis&#xD;
      (ALS) in a 15-month study of 44 patients with ALS. At the end of the trial, about 30 percent&#xD;
      of the patients that took riluzole had died, while all those receiving riluzole plus lithium&#xD;
      had survived. the lithium group had slower progression as measure by a test of breathing&#xD;
      (FVC) and strength.&#xD;
&#xD;
      This study will determine whether lithium in combination with riluzole delay progression of&#xD;
      patients with amyotrophic lateral sclerosis disease in comparison of an historical cohort of&#xD;
      ALS patients treated with riluzole alone.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival in patients with ALS treated with lithium and riluzole compared to historical cohort (patients treated with riluzole alone )</measure>
    <time_frame>15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional Assessment Change in ALS Functional Rating Score (ALSFRS-R slope)</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle Strength Change in MMT score (MMT slope)</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline of respiratory function determined as SVC over the 15 month treatment period</measure>
    <time_frame>15 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lithium</intervention_name>
    <description>lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of clinically possible, clinically probable laboratory-supported, clinically&#xD;
             probable or clinically definite ALS (according to WNF EL Escorial diagnostic criteria,&#xD;
             revised according to the AIRLIE House Conference 1998)&#xD;
&#xD;
          -  Concomitant standard Riluzole therapy (50mg twice daily)&#xD;
&#xD;
          -  patients included in ALS reference center&#xD;
&#xD;
          -  women of childbearing age be non-lactating and surgically sterile or using a highly&#xD;
             effective method of birth control and have a negative pregnancy test&#xD;
&#xD;
          -  capable of thoroughly understanding all information given and giving full informed&#xD;
             consent according to GCP&#xD;
&#xD;
          -  Patients with gastrostomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  evidence of major psychiatric disorder or clinically evident dementia precluding&#xD;
             evaluation of symptoms&#xD;
&#xD;
          -  any medical condition known to contre-indicate lithium treatment (dysthyroid,&#xD;
             cardiopathy, renal insufficiency)&#xD;
&#xD;
          -  presence of any concomitant life-threatening disease or impairment likely to interfere&#xD;
             with functional assessment&#xD;
&#xD;
          -  known hypersensitivity to any component of the study drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lucette Lacomblez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pitié-Salpêtrière Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>October 30, 2012</last_update_submitted>
  <last_update_submitted_qc>October 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Amyotrophic lateral sclerosis</keyword>
  <keyword>Lithium</keyword>
  <keyword>Survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

